AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...

AbbVie (NYSE:ABBV) said it has received FDA approval for its intravenous antibiotic treatment Emblaveo. The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with ...

AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

Metronidazole is added if anaerobic activity is required for bariatric surgeries involving the ileum. Intravenous is preferred over topical, subcutaneous or mechanical bowel preparation as the ...

Antibiotic regimens prospectively studied with little to no activity against anaerobic bacteria have uniformly performed well, while regimens containing metronidazole and doxycycline, which should ...